Content area

Abstract

Key message

CYP72D19, the first functional gene of the CYP72D subfamily, catalyzes the C-2 hydroxylation of abietane-type diterpenoids.

The abietane-type diterpenoids, e.g., triptolide, tripdiolide, and 2-epitripdiolide, are the main natural products for the anti-tumor, anti-inflammatory, and immunosuppressive activities of Tripterygium wilfordii, while their biosynthetic pathways are not resolved. Here, we cloned and characterized the CYP72D19-catalyzed C-2 hydroxylation of dehydroabietic acid, a compound that has been proven to be a biosynthetic intermediate in triptolide biosynthesis. Through molecular docking and site-directed mutagenesis, L386, L387, and I493 near the active pocket were found to have an important effect on the enzyme activity, which also indicates that steric hindrance of residues plays an important role in function. In addition, CYP72D19 also catalyzed a variety of abietane-type diterpenoids with benzene ring, presumably because the benzene ring of the substrate molecule stabilized the C-ring, allowing the protein and the substrate to form a relatively stable spatial structure. This is the first demonstration of CYP72D subfamily gene function. Our research provides important genetic elements for the structural modification of active ingredients and the heterologous production of other 2-hydroxyl abietane-type natural products.

Details

Title
CYP72D19 from Tripterygium wilfordii catalyzes C-2 hydroxylation of abietane-type diterpenoids
Author
Gao, Jie 1 ; Ma, Lin 2 ; Liu, Yuan 2 ; Tu, Lichan 3 ; Wu, Xiaoyi 2 ; Wang, Jian 4 ; Li, Dan 5 ; Zhang, Xianan 2 ; Gao, Wei 2 ; Zhang, Yifeng 4   VIAFID ORCID Logo  ; Liu, Changli 2 

 Capital Medical University, School of Traditional Chinese Medicine, Beijing, China (GRID:grid.24696.3f) (ISNI:0000 0004 0369 153X); Chinese Academy of Chinese Medical Sciences, National Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, National Resource Center for Chinese Materia Medica, Beijing, China (GRID:grid.410318.f) (ISNI:0000 0004 0632 3409) 
 Capital Medical University, School of Traditional Chinese Medicine, Beijing, China (GRID:grid.24696.3f) (ISNI:0000 0004 0369 153X) 
 Hangzhou City University, Key Laboratory of Novel Targets and Drug Study for Neural Repair of Zhejiang Province, School of Medicine, Hangzhou, China (GRID:grid.24696.3f) 
 Chinese Academy of Chinese Medical Sciences, National Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, National Resource Center for Chinese Materia Medica, Beijing, China (GRID:grid.410318.f) (ISNI:0000 0004 0632 3409) 
 Capital Medical University, School of Pharmaceutical Sciences, Beijing, China (GRID:grid.24696.3f) (ISNI:0000 0004 0369 153X) 
Pages
1733-1744
Publication year
2023
Publication date
Nov 2023
Publisher
Springer Nature B.V.
ISSN
07217714
e-ISSN
1432203X
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2874637591
Copyright
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.